Date:11/10/2010

ts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended September 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.CONTACTS:Investors:Patty Eisenhaur(973) 355-8141Media:Charlie Mayr(973) 355-8483(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)

'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Watson To Present At The 2010 Credit Suisse Healthcare Conference
2. Watson Confirms Crestor® Patent Challenge
3. Watsons Generic Version of Lotrel ® Receives FDA Approval
4. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
5. Watson Reaches Settlement with Endo Over Opana® ER
6. Watson Confirms Azilect® Patent Challenge
7. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
8. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
9. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
10. Watsons Generic Yasmin® Receives FDA Approval
11. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics